3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
747
Carcinoma, Renal Cell
237
Urinary Bladder Neoplasms
212
Carcinoma, Transitional Cell
115
Breast Neoplasms
100
Kidney Neoplasms
97
Neoplasms
91
Carcinoma, Non-Small-Cell Lung
86
Melanoma
82
Ovarian Neoplasms
81
Colorectal Neoplasms
76
Neoplasm Metastasis
69
Non-Muscle Invasive Bladder Neoplasms
58
Lung Neoplasms
58
Pancreatic Neoplasms
49
Endometrial Neoplasms
46
Sarcoma
43
Stomach Neoplasms
42
Uterine Cervical Neoplasms
41
Carcinoma, Hepatocellular
36
Adenocarcinoma
35
Wilms Tumor
33
Esophageal Neoplasms
33
Triple Negative Breast Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
31
Head and Neck Neoplasms
29
Testicular Neoplasms
25
Metastatic Castration-resistant Prostate Cancer
25
Disease
24
Colonic Neoplasms
24
Interventions
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
enfortumab vedotin
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Urothelial Cancer
×
Genitourinary
×
90 days
×
Clear all
NCT03547973
2026-03-16
TROPHY U-01
Gilead Sciences
Phase 2
Recruiting
827 enrolled
1 FDA